TTrialPathMatch Me to Trials
← Back to trials
RecruitingObesityOverweight and/or ObesityKnee Osteoarthritis

A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)

Eligible age

18+ yrs

Accepts

All genders

Locations

4 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.

Sponsor: Pfizer

You may qualify if…

  • ✓ Adults 18 years of age or older, or the minimum age of consent according to local regulations.
  • ✓ Body mass index of at least 27 kg/m² at Screening.
  • ✓ Currently meets American College of Rheumatology (ACR) Criteria for knee OA.
  • ✓ Pain due to knee OA.
  • ✓ Knee radiograph consistent with knee osteoarthritis and Kellgren-Lawrence Grade 2 or 3.
  • ✓ Willingness to complete the required analgesic washout.
  • ✓ History of at least 1 self-reported unsuccessful dietary effort to lose body weight.
  • ✓ HbA1c value at Screening of:

You may not qualify if…

  • ✕ Self-reported body weight increase or decrease greater than 5% within 90 days before Screening.
  • ✕ For participants with T2D at Screening only:
  • ✕ Diabetic maculopathy, proliferative diabetic retinopathy, or severe non-proliferative diabetic retinopathy requiring immediate intervention
  • ✕ Known clinically significant gastric-emptying abnormality, history of acute or chronic pancreatitis, or active symptomatic gallbladder disease.
  • ✕ Personal history or first-degree family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
  • ✕ Significant active or unstable psychiatric disorder.
  • ✕ Condition or knee disorder that could confound assessment of target-knee pain
  • ✕ Prior target-knee replacement, planned target-knee replacement, or planned elective knee surgery during the study.

Where it's recruiting

Alabama

Birmingham

Arizona

Tucson

Florida

Miami

Source: ClinicalTrials.gov · NCT07915609 · last updated 2026-11-04

A Study to Learn About Berobenatide Given Once Weekly in Adults With K · TrialPath